Welcome to our dedicated page for EyePoint Pharmaceuticals news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint Pharmaceuticals stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. The company is committed to developing and commercializing ophthalmic products aimed at treating serious retinal diseases. EyePoint leverages its proprietary Durasert® technology, a sustained intraocular drug delivery system, to create treatments that can provide continuous therapeutic effects for extended periods.
EyePoint Pharmaceuticals has made significant strides in the field of retinal disease treatments. Its lead product candidate, DURAVYU™ (previously known as EYP-1901), is an investigational treatment for VEGF-mediated retinal diseases. This product combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert® technology to offer sustained delivery and improved patient outcomes. DURAVYU™ is currently undergoing clinical trials for conditions such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).
The company also has several other promising candidates in its pipeline, including EYP-2301, a TIE-2 agonist, and razuprotafib, formulated with Durasert® technology to potentially enhance treatment outcomes for serious retinal diseases.
EyePoint’s innovative approach extends beyond product development to strategic partnerships and collaborations. The company has secured exclusive licenses for vorolanib from Equinox Sciences for all ophthalmic uses outside of China, Macao, Hong Kong, and Taiwan. Additionally, EyePoint has FDA-approved products such as RETISERT® and YUTIQ® that are based on its proprietary drug delivery technology.
Financially, EyePoint Pharmaceuticals has shown a solid performance with total net revenue of $46.0 million for the year ended December 31, 2023, compared to $41.4 million for the previous year. This growth is driven primarily by revenues from royalties and collaborations. The company has also strengthened its financial position with $331.1 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
EyePoint is dedicated to driving innovation in ophthalmology and improving the quality of life for patients with serious eye conditions. With a focus on advancing its robust pipeline through clinical development, EyePoint Pharmaceuticals continues to make headway in addressing unmet medical needs in retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) and Rallybio Corporation have announced a research collaboration focused on the sustained delivery of Rallybio's complement component 5 (C5) inhibitor using EyePoint's Durasert technology. This partnership aims to develop a long-acting treatment for geographic atrophy, an advanced form of age-related macular degeneration leading to vision loss. EyePoint's Durasert technology offers a potential alternative to existing therapies, requiring less frequent injections. Approximately 1 million people in the U.S. are affected by geographic atrophy, highlighting the significant unmet medical need for effective treatments.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call scheduled for March 2, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2022 financial results along with recent corporate developments.
The company's pipeline includes EYP-1901, an investigational treatment in Phase 2 clinical trials utilizing its Durasert® technology for sustained intraocular drug delivery. EyePoint has a track record with four FDA-approved products, including YUTIQ® for posterior segment uveitis, enhancing its position in the ophthalmic therapeutics market.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced on February 16, 2023, the granting of non-statutory stock options to two new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan, in compliance with NASDAQ Listing Rule 5635(c)(4). A total of 6,000 stock options were issued at an exercise price of $3.70 per share, equal to the closing price on the grant date. The options will vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments. The company is focused on therapeutics for serious eye disorders, leveraging its Durasert® technology.
EyePoint Pharmaceuticals has announced a lease agreement to build a 40,000-square-foot GMP manufacturing facility in Northbridge, Massachusetts, aimed at boosting the production of its retinal disease therapies, particularly EYP-1901 and YUTIQ. The facility is expected to be operational by the second half of 2024, bolstered by $1.9 million in state and local grants, with rent commencing after occupancy. This strategic investment aligns with EyePoint’s commitment to enhancing its manufacturing capabilities and meeting global clinical demands.
CEO Nancy Lurker emphasized that this facility will be vital for clinical development and commercial production, thereby supporting long-term shareholder value.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the grant of non-statutory stock options to two new employees as part of an inducement award. On January 13, 2023, the company approved stock options for a total of 4,000 shares, each with an exercise price of $5.04, reflecting the stock's closing price on that date. These options vest over four years, with an initial 25% vesting after one year and the remainder in monthly installments. This move aligns with NASDAQ Listing Rule 5635(c)(4) and aims to attract talented personnel to support EyePoint's commitment to developing therapeutics for serious eye disorders.
EyePoint Pharmaceuticals (NASDAQ: EYPT) provided a business update and clinical timelines for 2023, highlighting ongoing Phase 2 trials for its lead product EYP-1901, targeting wet AMD and NPDR. The company estimates 2022 net product revenue exceeding $39.5 million, up from $35.3 million in 2021, with cash reserves around $144 million. Key milestones include topline data from the DAVIO 2 trial expected in 4Q 2023. However, changes in Medicare reimbursement for DEXYCU may significantly impact future revenues.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the promotion of Dr. Jay S. Duker to President while retaining his role as Chief Operating Officer. Dr. Duker has been instrumental in leading the company’s clinical pipeline, achieving positive results in the Phase 1 DAVIO trial for wet age-related macular degeneration (AMD) and initiating two Phase 2 trials for the investigational drug EYP-1901. EyePoint focuses on developing treatments for serious eye disorders, leveraging its Durasert® technology for sustained drug delivery.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced on December 15, 2022, the grant of non-statutory stock options to a new employee as an inducement award. The company issued options to purchase up to 3,000 shares at an exercise price of $2.68 per share, based on the stock's closing price on the grant date. The options vest over four years, with a quarter vesting after one year and the rest in monthly installments, contingent on the employee's continued service.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the grant of non-statutory stock options totaling 10,700 shares to two new employees as a part of their inducement awards. This follows NASDAQ Listing Rule 5635(c)(4) and aims to attract talent to the company. The options were granted at an exercise price of $4.42 per share, corresponding to the closing stock price on November 15, 2022. The options will vest over four years, with the first 25% vesting on the anniversary of the grant date. EyePoint is focused on developing treatments for serious eye disorders using its Durasert® technology.
FAQ
What is the current stock price of EyePoint Pharmaceuticals (EYPT)?
What is the market cap of EyePoint Pharmaceuticals (EYPT)?
What does EyePoint Pharmaceuticals, Inc. (EYPT) specialize in?
What is DURAVYU™?
Where is EyePoint Pharmaceuticals headquartered?
What are the key products in EyePoint's pipeline?
How did EyePoint Pharmaceuticals perform financially in 2023?
What is the Durasert® technology?
Has EyePoint Pharmaceuticals received FDA approval for any products?
What are the geographical operational footprints of EyePoint Pharmaceuticals?
What is EyePoint's strategy for future growth?
How does EyePoint Pharmaceuticals generate revenue?
